Status:
RECRUITING
StrataCTX® as a Steroid Sparing Device
Lead Sponsor:
Columbia University
Conditions:
CTCL
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
The purpose is to determine if StrataCTX® can be used as a steroid sparing agent for the treatment of cutaneous reactions related to, cutaneous T Cell lymphoma (CTCL) and chemotherapy/immunotherapy tr...
Detailed Description
Topical steroids are the mainstays of treatment for many cutaneous reactions and disorders. Steroids are known to cause many side effects and few effective pharmacologic alternatives exist. Contact de...
Eligibility Criteria
Inclusion
- Age ≥ 18 years
- Ability to sign informed consent document
- Patient with a diagnosis of CTCL who have contact dermatitis to topical mechlorethamine gel
- Patients with a diagnosis of CTCL who have intractable pruritis
- Patients with a diagnosis of CTCL who rely heavily on topical steroids for symptomatic relief
- Patients on chemo/immunotherapy with drug induced rash
Exclusion
- Patients currently undergoing radiotherapy
- Patients currently receiving oral steroids
- Patients who are unable to apply topical medications
Key Trial Info
Start Date :
July 7 2021
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
August 1 2026
Estimated Enrollment :
70 Patients enrolled
Trial Details
Trial ID
NCT04087629
Start Date
July 7 2021
End Date
August 1 2026
Last Update
October 2 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Columbia University Irving Medical Center
New York, New York, United States, 10032